Guest Editor(s)

• Dr. Wei Zhang

  The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.

  Website | E-mail

Special Issue Introduction

For years, clinicians and researchers have been trying to discover better ways to diagnose human diseases, especially cancer, which is a leading cause of death globally. For many cancers, early detection and precise diagnosis could significantly improve cancer-related mortality and healthcare cost burden. At present, tissue biopsy pathology and imaging analyses are often the gold standard for cancer diagnosis and detection. Although extremely useful, tissue-based approaches are limited by various factors such as their invasive nature, possible exposure to radiation, tissue inaccessibility, as well as intra-tumoral heterogeneity. Analysis of circulating cell-free DNA (cfDNA), i.e., DNA fragments released by tumor cells or due to processes like apoptosis and necrosis, offers a promising alternative for cancer biomarker discovery, considering that cfDNA contains tumor-derived genetic and epigenetic information. In this special issue, we are interested in publishing research articles, short communications, technical notes, and review papers in the general area of applying cfDNA in the diagnosis of diseases. Papers on human cancers and other chronic diseases are all welcome.

Submission Deadline

30 Jan 2020

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://jtggjournal.com/pages/view/author_instructions
For Online Submission, please login at http://www.oaemesas.com/jtgg
Submission Deadline: 30 Jan 2020
Contacts: Jingxiu Li, Assistant Editor, editor001@jtggjournal.com